# Environmental Assessment for Oxytetracycline Dihydrate Administered to Shrimp for Minor Use Minor Species

> **NIH FDA R01** · PHIBRO ANIMAL HEALTH CORPORATION · 2024 · $209,928

## Abstract

Summary/Abstract
PAHC is seeking approval from the U.S. Food and Drug Administration (FDA) Center for
Veterinary Medicine (CVM) of Terramycin® 200 for Fish Type A medicated article,
containing the active pharmaceutical ingredient (API) oxytetracycline, for use in penaeid
shrimp. The proposed indication is for the control of mortality in penaeid shrimp due to
necrotizing hepatopancreatits (NHP) associated with Hepatobacter penaei. The work
involved will include environmental assessment, conditions of use of the drug, exposure
assessment, effects assessment, risk characterization, and conclusions.

## Key facts

- **NIH application ID:** 10885517
- **Project number:** 1R01FD008145-01
- **Recipient organization:** PHIBRO ANIMAL HEALTH CORPORATION
- **Principal Investigator:** Sean Parker
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** FDA
- **Fiscal year:** 2024
- **Award amount:** $209,928
- **Award type:** 1
- **Project period:** 2024-02-10 → 2027-01-09

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10885517

## Citation

> US National Institutes of Health, RePORTER application 10885517, Environmental Assessment for Oxytetracycline Dihydrate Administered to Shrimp for Minor Use Minor Species (1R01FD008145-01). Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/grant/nih/10885517. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*